Fewer than a tenth of individuals that would benefit from GLP-1 drugs like Wegovy have access to them, states the WHO as it publishes its first recommendations on the therapies.
Considering in excess of 1,000,000,000 individuals worldwide now obese, it is advocating for increased and just availability to GLP-1 medication.
According to forecasts, over two billion will be living with obesity by 2030 unless action is taken.
"Our latest guidance recognises that excess weight is a long-term condition that can be addressed with holistic and continuous treatment," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are major obstacles to broad availability to the jabs that can aid individuals in losing considerable weight, explains the organization.
Skinny Jab Supply Crisis
Even in the current most optimistic case, the manufacturing of such drugs would only suffice for about 100 million people – under 10% of the global need, according to the health organization.
The recommendation calls on nations and manufacturers to expand access, by measures such as voluntary licensing.
The intellectual property rights on a key compound – the primary component of a leading brand – is scheduled to end in multiple countries in 2026.
The Way Weight-Loss Injections Function
The injections replicate a biological compound to slow digestion, reduce hunger and increase the sense of being full so individuals eat less.
Patients commonly start to lose weight after several weeks of beginning the once-weekly jabs.
Evidence points to patients may see weight return after a year of stopping the medication, as their usual food cravings return.
Being carrying excess weight increases your chance for developing diseases, such as diabetes, cardiovascular issues, brain attack, and some malignancies.
Obesity affects individuals in every country and was responsible for millions of fatalities worldwide in 2024, per the health agency.
